Neovasc Inc.

Shockwave Medical plans to acquire Neovasc for up to $147m and help bring the Reducer angina device to the US market. Under the terms of the agreement, announced on 17 January, Shockwave will pay N

Neovasc is focused on bringing its Reducer coronary device to the US to treat cardiac angina – chest pain caused by a lack of blood flow to the heart muscle. “There are no good interventional options

Neovasc Inc. is persevering with the international commercialization of its Reducer transcatheter device to treat angina while its path to US commercialization remains uncertain. The Vancouver-based

Canadian device firm Neovasc Inc. is still pondering its next steps after a US Food and Drug Administration advisory panel declined to endorse the company’s Reducer to treat angina in certain patien